Peptides FAQ
Peptides are short chains of amino acids. Some are proven, FDA-approved medicines; most marketed wellness peptides are not. A 2026 interim policy lets six be compounded on prescription, but that is not approval or proof they work. Nothing on Beiing is medical advice, and Beiing never publishes dosing.
Short, sourced answers about peptides: what they are, whether they are legal after the 2026 HHS policy, whether they work, and how to stay safe.
The questions people ask most, each answered in a few cited sentences.
Key takeaways
- Approved, compounded and 'research use only' products carry the same names but very different protection.
- The 2026 policy changed access, not evidence.
- Report side effects from any medicine to FDA MedWatch.
Where to go next
For legal status by compound, see the status tracker. For how strong the research is, see the evidence ladder. For a single compound, open its profile from the section hub.
Frequently asked questions
What is a peptide?
A short chain of amino acids, usually fewer than about fifty, that the body uses as a signal. Insulin and GLP-1 are peptides.
Are peptides safe?
It depends entirely on which peptide and where it comes from. FDA-approved peptide medicines have reviewed safety data for their approved uses. Most marketed wellness peptides do not have adequate human safety data, and grey-market products may not contain what the label says.
Is BPC-157 legal after the October 2026 HHS policy?
It can now be compounded by a licensed pharmacist or physician for an individual patient with a prescription, under the policy's conditions. It is still not FDA-approved, and 'research use only' BPC-157 sold online is still not legal to sell for use in people.
Which peptides does the 2026 policy cover?
Six: BPC-157, TB-500, KPV, MOTS-c, Epitalon and Semax, each only in permitted forms and one peptide per product.
Does the policy mean the FDA thinks these peptides work?
No. The notice states that compounded drugs are not FDA-approved and that the FDA does not review their safety or effectiveness. FDA scientists objected to the policy on safety grounds.
What does 'research use only' mean?
It is a label used to sell chemicals for laboratory research. It is not a safety or quality assurance, and products sold this way are not legal to sell for use in people.
Are compounded semaglutide and tirzepatide still available?
The shortages that allowed widespread compounded copies ended in 2024 and 2025, and the temporary allowance ended in 2025. Compounded GLP-1 products are not FDA-approved. Ask a clinician or pharmacist about your specific situation.
Are peptides banned in sport?
Many are. USADA lists BPC-157 as prohibited under WADA's S0 category. A prescription does not change anti-doping rules; check any substance on Global DRO.
Why doesn't Beiing give doses?
Dosing is a clinical decision that depends on the person and the use. For unapproved compounds, publishing doses would amount to instructions for using unregulated drugs.
How do I report a side effect?
Through FDA MedWatch, and tell the prescriber or pharmacist involved. The interim policy requires compounders to report serious adverse events too.
Who writes and reviews this section?
Beiing's writers and researchers, against primary sources such as the Federal Register, FDA, USADA and peer-reviewed research. Pages show when they were last reviewed, and corrections are logged openly.
Related on Beiing
- Peptide status tracker - Legal status by compound.
- The evidence ladder - Evidence strength by compound.
- How Beiing rates peptide evidence - The five evidence levels used across this section.
- Peptides & Human Biology - The hub for every page in this section.
- Editorial Standards - How our content is researched and reviewed.
Sources
- Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Federal Register document 2026-22192, docket HHS-OASH-2026-0496) - U.S. Department of Health and Human Services, via the Federal Register
- BPC-157: What athletes should know about the prohibited experimental peptide - U.S. Anti-Doping Agency (USADA)
- MedWatch: report a side effect or product problem - U.S. Food and Drug Administration
- FDA winds down GLP-1 compounding policies (1 April 2025) - TechTarget Pharma Life Sciences
- AP report: FDA scientists opposed the move to ease peptide access - Associated Press, via PBS NewsHour
- Drugs@FDA - approved drug products and labels - U.S. Food and Drug Administration
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.